Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 1, Issue 4, 2015, Pages 455-463

  Forlenza, Orestes V ^a   Radanovic, Marcia ^a   Talib, Leda L ^a   Aprahamian, Ivan ^a   Diniz, Breno S ^b   Zetterberg, Henrik ^c,d   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Amyloid ; Biomarkers; Cerebrospinal fluid; Mild cognitive impairment; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THREONINE;

AGED; ALZHEIMER DISEASE; AMYLOID BETA PROTEIN[1-42] CEREBROSPINAL FLUID LEVEL; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PREDICTION; PREDICTIVE VALUE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TAU PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 84949551565     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.09.003     Document Type: Article

References (52)

1. Prince M., Bryce R., Albanese E., Wimo A., Ribeiro W., Ferri C.P. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013, 9:63-75.
2. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
3. Zetterberg H., Blennow K. Cerebrospinal fluid biomarkers for Alzheimer's disease: More to come?. J Alzheimers Dis 2013, 33:S361-S369.
4. Koopman K., LeBastard N., Martin J.J., Nagels G., DeDeyn P.P., Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau (181P). Neurochem Int 2009, 55:214-218.
5. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413. Alzheimer's Disease Neuroimaging Initiative.
6. Forlenza O.V., Diniz B.S., Gattaz W.F. Diagnosis and biomarkers of predementia in Alzheimer's disease. BMC Med 2010, 8:89.
7. Mueller S.G., Weiner M.W., Thal L.J., Petersen R.C., Jack C., Jagust W., et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005, 15:869-877.
8. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johson-Wood K., Galasko D., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995, 38:643-648.
9. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993, 61:1828-1834.
10. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: A biochemical marker for axonal degeneration in Alzheimer disease?. Mol Chem Neuropathol 1995, 26:231-245.
11. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1:213-225.
12. Blennow K., Hampel H. Cerebrospinal fluid markers for incipient Alzheimer's disease. Lancet Neurol 2003, 2:605-613.
13. Dubois B., Feldman H.H., Jacova C., Dekosky S.T., Barberger-Gateau P., Cummings J., et al. Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6:734-746.
14. Jack C.R., Alber M.S., Knopman D.S., McKhann G.M., Sperling R.A., Carrillo M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
15. Höglund K., Fourier A., Perret-Liaudet A., Zetterberg H., Blennow K., Portelius E. Alzheimer's disease: Recent biomarker developments in relation to updated diagnostic criteria. Clin Chim Acta 2015, 449:3-8.
16. Roth M., Tym E., Mountjoy C.Q., Huppert F.A., Hendrie H., Verma S., et al. CAMDEX: A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection dementia. Br J Psychiatry 1986, 149:698-709.
17. Folstein M., Folstein S., McHugh P.R. Mini-mental state: A practical method for grading the cognitive state of patients. J Psychiatr Res 1975, 12:189-198.
18. Fuld P. Guaranteed stimulus processing in the evaluation of memory and learning. Cortex 1980, 16:255-271.
19. Army individual test battery. Manual of directions and scoring 1944, War Department, Adjutant General's Office, Washington, DC.
20. Erzigkeit H. SKT: A short cognitive performance test for assessing deficits of memory and attention. User's Manual 2001, Geromed GmbH, Erlangen, Germany. 23rd ed.
21. Flaks M.K., Yassuda M.S., Regina A.C., Cid C.G., Camargo C.H., Gattaz W.F., et al. The short cognitive performance test (SKT): A preliminary study of its psychometric properties in Brazil. Int Psychogeriatr 2006, 18:121-133.
22. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatr 1960, 23:56-62.
23. Diniz B.S., Nunes P.V., Yassuda M.S., Pereira F.S., Flaks M.K., Viola L.F., et al. Mild cognitive impairment: Cognitive screening or neuropsychological assessment?. Rev Bras Psiquiatr 2008, 30:316-321.
24. Forlenza O.V., Diniz B.S., Talib L.L., Radanovic M., Yassuda M.S., Ojopi E.B., et al. Clinical and biological predictors of Alzheimer's disease in patients with amnestic mild cognitive impairment. Rev Bras Psiquiatr 2010, 32:216-222.
25. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
26. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., et al. Current concepts in mild cognitive impairment. Arch Neurol 2001, 58:1985-1992.
27. Diagnostic and statistical manual of mental disorders (DSM-IV) 2000, American Psychiatric Association, American Psychiatric Association, Washington DC. 4th ed.
28. Loewenstein D.A., Amigo E., Duara R. A new scale for the assessment of functional status in Alzheimer's disease and related disorders. J Gerontol 1989, 4:114-121.
29. Pereira F.S., Oliveira A.M., Diniz B.S., Forlenza O.V., Yassuda M.S. Cross-cultural adaptation, reliability and validity of the DAFS-R in a sample of Brazilian older adults. Arch Clin Neuropsychol 2010, 25:335-343.
30. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012, 69:98-106.
31. van Harten A.C., Visser P.J., Pijnenburg Y.A., Teunissen C.E., Blankenstein M.A., Scheltens P., et al. Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints. Alzheimers Dement 2013, 9:481-487.
32. Andreasen N., Vanmechelen E., van de Voorde A., Davidsson P., Hesse C., Tarvonen S., et al. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: A community based follow-up study. J Neurol Neurosurg Psychiatr 1998, 64:298-305.
33. Galasko D., Clark C., Chang L., Miller B., Green R.C., Motter R., et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology 1997, 48:632-635.
34. Galasko D., Chang L., Motter R., Clark C.M., Kaye J., Knopman D., et al. High cerebrospinal fluid tau and low amyloid b42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998, 55:937-945.
35. Hulstaert F., Blennow K., Ivanoiu A., Schoonderwaldt H.C., Riemenschneider M., De Deyn P.P., et al. Improved discrimination of AD patients using b-amyloid (1-42) and tau levels in CSF. Neurology 1999, 52:1555-1562.
36. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winbald B., et al. Evaluation of CSF-tau and CSF-Aß42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001, 58:373-379.
37. Weiner M.W., Veitch D.P., Aisen P.S., Beckett L.A., Cairns N.J., Green R.C., et al. The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimers Dement 2013, 9:e111-e194. Alzheimer's Disease Neuroimaging Initiative.
38. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 2006, 5:228-234.
39. Hertze J., Minthon L., Zetterberg H., Vanmechelen E., Blennow K., Hansson O. Evaluation of CSF biomarkers as predictors of Alzheimer's disease: A clinical follow-up study of 4.7 years. J Alzheimers Dis 2010, 21:1119-1128.
40. Struyfs H., van Broeck B., Timmers M., Fransen E., Sleegers K., van Broeckhoven C., et al. Diagnostic accuracy of cerebrospinal fluid amyloid-β isoforms for early and differential dementia diagnosis. J Alzheimers Dis 2015, 45:813-822.
41. Irwin D.J., Trojanowski J.Q., Grossman M. Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease. Front Aging Neurosci 2013, 5:6.
42. Kaerst L., Kuhlmann A., Wedekind D., Stoeck K., Lange P., Zerr I. Cerebrospinal fluid biomarkers in Alzheimer's disease, vascular dementia and ischemic stroke patients: A critical analysis. J Neurol 2013, 260:2722-2727.
43. Stefani A., Brusa L., Olivola E., Pierantozzi M., Martorana M. CSF and clinical hallmarks of subcortical dementias: Focus on DLB and PDD. J Neural Transm 2012, 119:861-875.
44. Rosén C., Hansson O., Blennow K., Zetterberg H. Fluid biomarkers in Alzheimer's disease-Current concepts. Mol Neurodegener 2013, 8:20.
45. Seeburger J.L., Holder D.J., Combrinck M., Joachim C., Laterza O., Tanen M., et al. Cerebrospinal fluid biomarkers distinguish postmortem confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort. J Alzheimers Dis 2015, 44:525-539.
46. Molinuevo J.L., Blennow K., Dubois B., Engelborghs S., Lewczuk P., Perret-Liaudet A., et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 2014, 10:808-817.
47. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Figurski M., Coart E., Blennow K., et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 2011, 121:597-609. Alzheimer's Disease Neuroimaging Initiative.
48. Mattsson N., Andreasson U., Persson S., Arai H., Batish S.D., Bernardini S., et al. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 2011, 7:386-395.
49. Mattsson N., Andreasson U., Persson S., Carrillo M.C., Collins S., Chalbot S., et al. CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement 2013, 9:251-261. Alzheimer's Association QC Program Work Group.
50. Fagan A.M., Shaw L.M., Xiong C., Vanderstichele H., Mintun M.A., Trojanowski J.Q., et al. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 2011, 68:1137-1144.
51. Palmqvist S., Zetterberg H., Blennow K., Vestberg S., Andreasson U., Brooks D.J., et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. JAMA Neurol 2014, 71:1282-1289.
52. Blennow K., Dubois B., Fagan A.M., Lewczuk P., de Leon M.J., Hampel H. Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement 2015, 11:58-69.